GentaGel

Company Overview

Snapshot

Founded in July 2021 by Abraham Domb, GentaGel operates with 1–10 employees. The company is currently in the Pre-Funding stage and is focused on advancing its GentaGel-LR product through clinical trials.

Business overview

GentaGel is a Health Tech & Life Sciences company developing a local slow-release antibiotic treatment. Its core product, GentaGel-LR, is an injectable solution designed to continuously release antibiotics for up to 60 days, achieving therapeutic concentrations in the administered area without systemic detection. This technology aims to provide effective antibiotic treatment while minimizing side effects and reducing healthcare costs, primarily serving the pharmaceutical and medical device industries.

Company Intelligence Q&A

What is GentaGel's primary product?

GentaGel's primary product is GentaGel-LR, a slow-release antibiotic treatment designed for local administration.

When was GentaGel founded?

GentaGel was founded in July 2021.

Who is a co-founder of GentaGel?

Abraham Domb is a co-founder of GentaGel.

What is the current product stage of GentaGel-LR?

GentaGel-LR is currently in the Clinical Trial product stage, meaning it is undergoing testing in human subjects to evaluate its safety and efficacy before potential market approval.

What problem does GentaGel aim to solve with its technology?

GentaGel aims to provide an effective antibiotic treatment that avoids systemic side-effects and reduces the cost of care by delivering antibiotics locally and continuously for an extended period.